CELL & GENE CAPACITY UPDATE VIDEOS
VintaBio Capacity Update July 2024: Cell & Gene Therapy
VintaBio has created open capacity for AAV clinical manufacturing through its streamlined VintaProcess platform which is an intensified adherent AAV process with very low impurities.
FUJIFILM Diosynth Biotechnologies Capacity Update July 2024: Cell & Gene Therapy
The capacity expansion project at our Thousand Oaks facility will add new cleanrooms, updated development labs, expanded QC labs, and high efficiency warehousing solutions.
WuXi Advanced Therapies Capacity Update July 2024: Cell & Gene Therapy
Learn how our expert and experienced team in Philadelphia supports cell therapy and viral vector production across a variety of modalities and stages of clinical and commercial manufacturing.
Alcami Capacity Update July 2024: Cell & Gene Therapy
Alcami offers method development, method validation and QC testing, as well as R&D testing support, leveraging our company’s extensive expertise in various testing platforms.
Biocentriq Capacity Update July 2024: Cell & Gene Therapy
Learn more about BioCentriq's state-of-the-art facilities, established track record in GMP drug product release, and customized solutions supported by a seasoned team with strong commitment to quality.
Andelyn Biosciences Capacity Update July 2024: Cell & Gene Therapy
To address the myriad of challenges that accompany AAV manufacturing, Andelyn uses a combination of reductionist and holistic approaches to perform end-to-end optimization for its platform.
Capacity Update July 2024: Cell & Gene Therapy
In addition to the immediate capacity for Draw-to-Thaw™ services in New York, NY, and Louisville, KY, we have openings for process and analytical development work in its Houston, TX facility.
Cellistic Capacity Update July 2024: Cell & Gene Therapy
Explore the latest insights and challenges in the cell therapy space, and learn how Cellistic overcomes these challenges with iPSC, focusing on regulatory strategies and cutting-edge capabilities.
Cellistic Capacity Update May 2024: Cell & Gene Therapy
Examine the time saving factor of using Cellistic's predeveloped Pulse & Echo platforms, the IP considerations with iPCSs, and Cellistic's involvement in developing clinical therapies.
Theragent Capacity Update May 2024: Cell & Gene Therapy
Gain insight into our proprietary digital platform that de-risks clinical trials, expedites manufacturing, offers full transparency to sponsors, and provides complete chain-of-custody assurance.
Andelyn Biosciences Capacity Update May 2024: Cell & Gene Therapy
Learn how our proven methodology and decades-long AAV database at the core of the AAV Curator™ Platform directly drives speed, maximizes yields, and delivers a high-quality product.
Pfizer CentreOne Capacity Update May 2024: Cell & Gene Therapy
Review Pfizer CentreOne’s overall gene & cell therapy capabilities, with a focus on their ability to help meet your complex viral vector needs.
WuXi Advanced Therapies Capacity Update May 2024: Cell & Gene Therapy
Review an update on our 400,000+ square foot campus in Philadelphia, Pennsylvania and the infrastructure dedicated to Cell & Gene Therapy development, testing and manufacturing.
Comprehensive Cell Solutions Capacity Update May 2024: Cell & Gene Therapy
Comprehensive Cell Solutions is a CGT focused division of New York Blood Center Enterprises with a Draw-To-Thaw™ portfolio of CDMO services strategically located throughout the US built upon on NYBC’s 60+ years of experience.
MilliporeSigma Capacity Update May 2024: Cell & Gene Therapy
Discover how we apply our 30 years of experience to enhance quality and de-risk viral vector production at any stage and knowhow to advance cell and gene therapies from pre-IND through routine supply.
Aldevron Capacity Update May 2024: Cell & Gene Therapy
Explore the new capacity and capabilities of our complete mRNA Ecosystem to offer streamlined services for process development, manufacture, and release of both mRNA drug substance and product.
Vernal Biosciences Capacity Update May 2024: Cell & Gene Therapy
Examine our platform analytical and process technologies designed to accelerate the development of your cell therapy, gene therapy, or vaccine drug product.
ReciBioPharm Capacity Update May 2024: Cell & Gene Therapy
Learn more about our global capabilities in Nucleic Acid, AAV, Lentivirus, Microbiome and Fill-Finish. We offer end-to-end GMP manufacturing under one roof through an integrated supply chain.
Resilience Capacity Update May 2024: Cell & Gene Therapy
With a strong network of 11 sites located across North America supporting 5 modalities, Resilience provides innovative solutions and services for established and emerging therapies.
AGC Biologics Capacity Update February 2024: Cell & Gene
In this presentation from the February 2024 OPCU event, learn more about the AGC Biologics’ global Cell and Gene network, track record, capabilities, and how it can provide support for any project.
Don't miss our next installment!
These conferences are ideal for professionals who have the authority to choose and manage CDMO relationships and need to secure capacity for their development or commercial programs.
How can we help?
Are you a supplier looking to present at our next event?